Iain De Havilland is a visionary entrepreneur and pioneer in NAD+ therapy, holistic health, and wellness innovation. His passion as a lifestyle aficionado and curiosity about longevity science led him to establish the NADclinic Group, Europe’s No1 NAD+ brand, and a recognised global leader in regenerative NAD+ based cellular therapy. 

Iain first discovered NAD+ after co-founding a 5-star rehabilitation centre in Europe, where he introduced NAD+ injectables, as a groundbreaking therapy supporting executive burnout and as a lifestyle detox protocol. After witnessing the incredible results first hand and becoming a regular NAD+ IV user himself, Iain recognised NAD+’s potential as a much broader cellular rejuvenation therapy.  Iain subsequently invested in several years of extensive research and development in NAD+ as a human performance, wellness and longevity intervention. 

Over the past decade and collaborating with many leading international orthomolecular experts & scientists, Iain has developed an extensive range of proprietary longevity protocols targeting anti-senescence, human performance, and optimised healthspan, under the NADclinic brand. In 2017, Iain formally launched NADclinic, which has since expanded across 40+ countries and five continents. Its premium regenerative health portfolio now also includes NAD+, Peptides, Exosomes, and a range of proprietary nutraceuticals and therapeutics. 

A seasoned CEO with over 20 years of international corporate finance experience, Iain excels in global networking, stakeholder engagement, and high-performance leadership. His innovation and strategic vision continues to drive NADclinic’s growth, with plans to aggressively expand its premium regenerative health products and services into the GCC, Latam and US markets in 2025.